Hepatocellular carcinoma in HCV - liver cirrhosis before and after successful DAA treatment

Abstract

Chronic hepatitis C virus (HCV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. The recent advancement of direct-acting Antiviral Agents (DAAs) in hepatitis C therapy, resulted in sustained virological response rates of over 90% in treated patients in different stages of liver fibrosis. The efficacy of DAAs treatment has also been confirmed in real-life cohorts that include subjects with decompensated cirrhosis and therefore seems a promising step to a significant reduction in the recurrence of HCC in patients who achieved complete destruction of the HCC nodules by local therapy. We present a 72-year old patient with HCV-related liver cirrhosis who successfully responded to DAAs treatment after complete destruction of an early HCC nodule.

Keywords

Hepatocellular carcinoma / hepatitis C virus infection / Direct-acting Antiviral Agents / hepatocellular carcinoma recurrence

References

[1] Poordad F,Trinh R,Zeuzem S.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis..N Engl J Med2014;370:1973-82

[2] Deeks ED.Ombitasvir/Paritaprevir/Ritonavir PlusDasabuvir: A Review in Chronic HCV Genotype 1 Infection..Drugs2015;75:1027-38

[3] Bourlière M,de Ledinghen V,Zoulim F.Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)..Lancet Infect Dis2015;15:397-404

[4] Backus L,Shahoumian TA,Mole LA.Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients..Antivir Ther2017;22:481-93

[5] Sulkowski MS,Di Bisceglie AM,Reddy KR.Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV Genotype 1 Infection..Gastroenterology2015;150:419-29 PMCID:PMC4727992

[6] Foster GR,Cheung MCM,Hudson BE.Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis..J Hepatol2016;64:1224-31

[7] Reig M,Perelló C,Ribeiro A.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy..J Hepatol2016;65:719-26

[8] Conti F,Scuteri A,Bolondi L.Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals..J Hepatol2016;65:727-33

[9] Kanwal F,Asch SM,Cao Y.Risk of hepatocellular cancer in HCV patients treated with direct-antiviral agents..Gastroenterology2017;153:996-1005

[10] Ioannou GN,Berry K.HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma..J Hepatol2017;68:25-32

[11] Krastev Z,Antonov K,Atanasova E.Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma..World J Gastroenterol2016;22:2630-5 PMCID:PMC4768209

[12] Guarino M,Ponziani FR,Lai Q.Recurrence of hepatocellular carcinoma after direct acting antiviral treatment for hepatitis C virus infection: Literature review and risk analysis..Dig Liver Dis2018;50:1105-14

[13] Ikeda K,Kobayashi M,Fujiyama S.Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma..Dig Dis Sci2017;62:2932-42

[14] Cabibbo G,Calvaruso V,Cannavò MR.Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals?.A prospective multicentre study. Aliment Pharmacol Ther2017;46:688-95

[15] Ogawa E,Nomura H,Higashi N.Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment..Aliment Pharmacol Ther2018;47:104-13

[16] Li T,Zhi XT,Dong ZR.Positive HBcAb is associated with higher risk of early recurrence and poorer survival aft er curative resection of HBV-related HCC..Liver Int2016;36:284-92

[17] Wu T,Tran TT.Isolated anti-HBc: The Relevance of Hepatitis B Core Antibody-A Review of New Issues..Am J Gastroenterol2017;112:1780-8